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ABSTRACT Pemphigus vulgaris (PV) is a life-threatening, autoimmune blistering dis-
ease of the skin and mucous membranes. The relationship between PV and human 
leukocyte antigen (HLA) has been studied in several reports. Previous reports have 
demonstrated that HLA-E polymorphisms may have a role in the susceptibility to 
various autoimmune diseases. Our aim was to evaluate the role of HLA-E gene poly-
morphisms in the pathogenesis of PV in a Turkish population. A total of 49 patients 
with PV and 50 healthy subjects were enrolled into the study. We sequenced and an-
alyzed the HLA-E gene from genomic DNA obtained from peripheral blood samples 
of the study groups. HLA-E haplotyping was performed by Sanger sequencing of PCR 
products of the HLA-E gene and HLA-E alleles determined by using SeqScape® soft-
ware according to the World Health Organization (WHO) Nomenclature Committee 
for Factors of the HLA System. The frequency of the HLA-E*0101/*0103X genotype in 
male patients with PV was found to be significantly higher than in men in the control 
group (P=0.023). In addition, the frequency of the HLA-E*0103X/*0103X genotype 
was significantly lower in patients with PV than the control group (P=0.040). We also 
detected that the frequency of the HLA-E*0101/*0103X genotype in patients with 
mucocutaneous type PV and the frequency of the HLA-E*0101/*0101 genotype in 
patients with mucosal type PV was significantly higher than those in other types of 
PV (P=0.001 and P=0.006). The results of this study indicate that carrying the HLA-
E*0101/0103X genotype may increase the risk of PV in male patients.
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INTRODUCTION
Pemphigus is a group of rare and life-threatening 
autoimmune bullous diseases of the skin and mucous 
membranes, characterized by intraepidermal blister-
ing. It is associated with pathogenic antibodies di-
rected against desmoglein (Dsg) 3 and/or Dsg1, two 
transmembrane components of desmosomes, which 
are cell-cell adhesion complexes (1).
Pemphigus is a rare disease with an incidence 
ranging from 0.7-5 new cases/year per million. Pem-
phigus vulgaris (PV) is the main clinical subtype of 
the disease. PV often affects individuals between the 
ages 40 and 60, and its main characteristics are flaccid 
blisters and erosions of the mucous membranes and 
the skin. The most characteristic clinical findings are 
painful erosions and ulcers in the oral mucosa (2).
Genetic susceptibility to PV has gradually become 
an area of interest after the publication of two reports 
on the increased incidence of HLA-A10 in the Japanese 
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and Jewish populations (3,4). Certain human leuko-
cyte antigen (HLA) class II alleles are more prevalent 
in patients with PV than in the general populations. 
Previous studies have demonstrated that HLA alleles 
DRB1*0402 and DQB1*0503 are positively associated 
with PV in multiple populations (5-7). Furthermore, 
some disease associations have been also reported 
with classical HLA class I (Ia) antigens, including HLA-
A10, B35, B44, and CW4 (4,8-12).
In the Turkish population, significant associa-
tions with DRB1*04, DRB1*14, DQB1*05, DPB1*0401, 
CW*01, DR14, DQ8, DQ4, B35, B44, CW4, and PV 
have been demonstrated in three different studies 
(10,13,14).
Only a very limited number of studies has been 
published on non-classical HLA class Ib alleles (HLA-
E, -F, -G) and PV, and only one of them on HLA-E and 
PV (15-17).
In humans, the location of the HLA-E genetic re-
gion is between the classical class I genes HLA-A and 
HLA-C on chromosome 6p21 (18). The HLA-E gene 
has been recently reported to have six alleles: HLA-
E*0101, HLA-E*0103X (HLA-E*01031, HLA-E*01032), 
HLA-E*0104, HLA-E*0105, HLA-E*0106, HLA-E*0107 
(19).
Regarding blistering diseases, a study from North 
America only pointed out that the homozygous gen-
otype HLA-E*0103X/0103X is associated with suscep-
tibility to PV in a cohort including Caucasian and Ash-
kenazi Jewish patients (17).
Herein we evaluate the potential association be-




A prospective case-control study was performed 
to evaluate the potential association between PV 
and HLA-E polymorphisms. The patients and controls 
were matched for age and sex and recruited over a 
12-month period. This study was conducted accord-
ing to the principles of the Declaration of Helsinki, ap-
proved by the local ethics committee, and was sup-
ported by the Scientific Research Unit of Karadeniz 
Technical University under project number 1002.
Patients and controls
We aimed to enroll, consecutively, all patients with 
a diagnosis of PV who were admitted to the clinics 
of the Department of Dermatology at the Faculty of 
Medicine at Karadeniz Technical University in 1-year 
period. The following criteria was used for inclusion: 
(i) a confirmed diagnosis of PV with clinical, histologi-
cal, and direct immunofluorescence findings, (ii) no 
additional autoimmune disorders, and (iii) informed 
consent.
Forty-nine patients with a diagnosis of PV (22 
women and 27 men with a mean age of 53.3 years, 
range: 23-79) were enrolled in the patient group. The 
control group consisted of 50 healthy age- and sex-
matched individuals (23 women and 27 men with a 
mean age of 53.2 years, range: 24-79). They had no 
known systemic diseases. Informed consent was also 
obtained. The source population for cases and con-
trols was the same.
Collection of data and samples
All cases and controls were visited by a dermatol-
ogist MD who registered demographic, clinical, and 
laboratory findings and other relevant data on a case 
report form. Venous blood samples were taken with 
ethylenediaminetetraacetic acid (EDTA) tubes from 
each of the individuals in both groups.
Genomic DNA isolation from the samples
Genomic DNA of participants was isolated using 
the classical salting-out method (20).
Haplotyping of the HLA-E gene by Sanger 
Sequencing 
The HLA-E gene (NM_005516) was amplified by 
polymerase chain reaction (PCR) using specific prim-
ers obtained by the Primer 3 program. Sequencing re-
actions were carried out by using BigDye® Terminator 
v3.1 Cycle Sequencing Kits and the ABI PRISM 3130 
DNA analyzer (Applied Biosystems, Foster City, CA, 
Table 1. The comparison of the frequencies of the human leukocyte antigen (HLA)-E genotypes between 
patients with pemphigus vulgaris and control subjects
HLA-E*0101/*0101 (%) HLA-E*0101/*0103X (%) HLA-E*0103X/*0103X (%)
PV Control P PV Control P PV Control P
Men 11.1 11.1 1.000 81.5 48.1 0.023 3.7 40.7 0.003
Women 27.3 30.4 1.000 45.5 43.5 1.000 27.3 26.1 1.000
Total 18.4 20.0 1.000 65.3 46.0 0.084 14.3 34.0 0.040
*PV: Pemphigus vulgaris
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USA). For analyses of sequencing data, SeqScape® soft-
ware v2.5 (Applied Biosystems, USA) was used (21).
Statistical Analysis
The SPSS 13.0 package program was used for sta-
tistical analyses. Constant variables in the data set 
were expressed as mean and Standard Deviation, 
while categorical variables were expressed as fre-
quency and percentage. The chi-square test was used 
in group comparisons of categorical variables. The in-
dependent samples test was used in two-group com-
parison of normally distributed constant variables, 
and the Mann-Whitney U test was used for non-nor-
mally distributed constant variables. Significance was 
defined as P<0.05.
RESULTS
Forty-nine Turkish patients with PV and 50 healthy 
control subjects were enrolled in the study. 
We determined the HLA-E genotypes and 
their frequencies in the patients with PV and 
control populations. The HLA-E genotypes 
were HLA-E*0101/*0101, HLA-E*0101/*0103X 
(*0101/*010301, *0101/*010302), HLA-E*0103X/
*0103X (*010301/*010301, *010301/*010302, 
*010302/*10302), and HLA-E*0101/*0106.
We compared the frequencies of these HLA-E 
genotypes between the patients and control sub-
jects. We found that patients and control subjects 
were more likely to type as HLA-E*0101/0103X het-
erozygous genotype (65.3 % of patients vs. 46.0% 
of controls; P=0.084). Patients with PV were signifi-
cantly less likely to type as HLA-E*0103X/0103X ho-
mozygous genotype than control subjects (14.3% of 
patients vs. 34.0% of controls; P=0.040) (Table 1). For 
HLA-E*0101/0101 homozygous genotype (18.4% of 
patients vs. 20.0% of controls; P=1.000), the difference 
was not statistically significant. There was only one 
patient with HLA-E*0101/0106 heterozygous geno-
type, while no control subjects had this genotype.
Regarding sex associations, we found that men 
in the patient group were less likely to type as HLA-
E*0103X/*0103X homozygous genotype than men 
in the control group (3.7% of male patients vs. 40.7% 
male controls; P=0.003) while women in both groups 
did not show a significant difference in terms of this 
or any other genotype. A statistically significant dif-
ference for male subjects was also found in the com-
parison of the frequencies of HLA-E*0101/0103X 
heterozygous genotype (81.5% of male patients vs. 
48.1% of male controls; P=0.023) (Table 1).
Regarding clinical types of PV, 38 of 49 (77.5%) pa-
tients had mucocutaneous PV, while 10 of 49 (20.4%) 
patients only had mucosal disease. We compared the 
frequencies of HLA-E genotypes between the pa-
tients and control subjects according to the clinical 
types of the disease. We found that patients with mu-
cosal PV were more likely to type as HLA-E*0101/0101 
homozygous genotype than patients with muco-
cutaneous PV (50% vs. 7.9%; P=0.006). Patients with 
mucocutaneous PV were more likely to type as HLA-
E*0101/0103X heterozygous genotype than patients 
with mucosal PV (78.9% vs. 20.0%; P=0.001). For the 
HLA-E*0103X/0103X homozygous genotype (13.2% 
vs. 20.0%; P=0.625), the difference was not statisti-
cally significant (Table 2).
DISCUSSION
In the present study, we found an association be-
tween HLA-E and PV. We found that the HLA-E*0103X/
0103X homozygous genotype was significantly less 
frequent in patients with PV, indicating that carrying 
this homozygous genotype might be a protective fac-
tor for PV. We also found that the HLA-E*0101/0103X 
heterozygous genotype was significantly more fre-
quent in men with PV, indicating that carrying this 
genotype enhanced the risk of PV in men. In addi-
tion, the latter genotype was also significantly more 
frequent in patients with mucocutaneous PV.
While PV is a rare autoimmune disease, a large 
number of studies in different populations have been 
published on the genetic susceptibility to it. They 
mostly showed that HLA class II antigens were more 
prevalent in patients with PV than in the general pop-
ulation (5-7,10,13,14).
Table 2. The comparison of the frequencies of the human leukocyte antigen (HLA)-E genotypes accord-
ing to the clinical types of pemphigus vulgaris
Mucocutaneous PV (n=38) Mucosal PV (n=10) P
HLA-E*0101/0101: n (%) 3 (7.9) 5 (50) 0.006
HLA-E*0101/0103X: n (%) 30 (78.9) 2 (20) 0.001
HLA-E*0103X/0103X: n (%) 5 (13.2) 2 (20) 0.625
HLA-E*0101/0106: n (%)           - 1 (10)
*PV: Pemphigus vulgaris
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There is only one study from North America on 
HLA-E polymorphisms and PV. Bhanusali et al. reported 
that the homozygous genotype HLA-E*0103X/0103X 
was associated with susceptibility to PV in a cohort 
including Caucasian and Ashkenazi Jewish patients 
(17). In contrast to this report, our study found that 
patients with PV were significantly less likely to type 
as the homozygous genotype HLA-E*0103X/0103X 
(14.3% of patients vs. 34.0% of controls; P=0.040), 
indicating that carrying this genotype might be a 
protective factor for PV in the Turkish population. The 
following factors could be speculated as the causes 
of this discrepancy: First of all, distribution of HLA-E 
alleles is different between the ethnic groups in these 
studies, and the subtle genetic difference might make 
it possible that genetic factors involved in the patho-
genesis of PV vary in these populations. Therefore, 
the putative HLA alleles involved in the pathogen-
esis of PV in Caucasian and Ashkenazi Jewish may be 
distinct from the HLA alleles in the Turkish popula-
tion. Secondly, the interaction between HLA alleles 
and different infectious agents or environmental al-
lergen across geographical regions might cause this 
discrepancy. Finally, the limited size of both studies 
might be another cause of this inconsistency.
In our study, we also found that male patients 
with PV were significantly more likely to type as HLA-
E*0101/0103X heterozygous genotype than men in 
the control group (81.5% of male patients vs. 48.1 % 
of male controls; P=0.023). This result indicates that 
carrying this genotype in men increases the risk of PV 
in the Turkish population. However, in Bhanusali et al., 
the difference between male subjects in those groups 
was not significant in terms of this genotype (17).
To the best of our knowledge, our study is the 
second report on the association of HLA-E polymor-
phism and PV. Our results do not support the findings 
of the first study, published by Bhanusali et al. These 
contrasting results may indicate how affected differ-
ent races and ethnicities are in the HLA-E gene poly-
morphisms. Moreover, the heterozygous genotype 
HLA-E*0101/*0106 was determined to be a different 
HLA-E genotype in our patient group; it was however 
not found in the former study. This finding shows the 
diversity among the patient group of our study and 
also supports the possibility of variations in HLA-E 
gene polymorphisms.
An increasing number of studies have shown that 
HLA-E polymorphisms may play an integral role in 
various autoimmune and inflammatory diseases, in-
cluding rheumatoid arthritis, type 1 diabetes melli-
tus, Behcet’s disease, multiple sclerosis, celiac disease, 
and psoriasis (22-7).
HLA-E is the least polymorphic molecule of all 
class I HLA genes and is characterized by a conserved 
peptide-binding groove (28,29). The functional roles 
of these polymorphisms reported in PV and other au-
toimmune diseases remain unclear. The HLA-E mol-
ecule can be recognized by a subset of HLA-restricted 
regulatory CD8+ T-cells in a T-cell receptor (TCR)-de-
pendent manner; this signaling pathway has been im-
plicated in the pathogenesis of autoimmune diseases 
(30). Experiments with a murine model of multiple 
sclerosis (experimental allergic encephalomyelitis; 
EAE) revealed that engagement of the TCR on regu-
latory CD8+ T cells by Qa-1 (HLA E in humans)-pep-
tide complexes triggers suppressive activity of these 
cells towards potentially autoreactive CD4+ T clones, 
while impairment of this interaction was associated 
with increased susceptibility to the development of 
EAE (31). Additionally, in vivo studies in patients with 
type 1 diabetes mellitus confirmed the essential role 
of the HLA-E restricted CD8+ T-cell-mediated pathway 
in the maintenance of peripheral self-tolerance (32). 
Regarding this recognition pathway, it was proposed 
that the HLA-E*0101 and HLA-E*0103 alleles might 
differ in their capacity to interact with TCR receptors 
on regulatory T-cells (17).
Furthermore, NK cells have been shown to be in-
volved in the regulation of autoreactive CD4+ T-cells 
via the Qa-1-NKG2A inhibitory pathway in experi-
mental murine models of rheumatoid arthritis and 
multiple sclerosis (33,34). Interruption of the interac-
tion between Qa-1 and CD94/NKG2A through anti-
NKG2A antibody administration or genetic disruption 
has been shown to result in up-regulated activity of 
NK cells against pathogenic CD4+ T-cells and associ-
ated with inhibition of the disease development. The 
results of these studies suggest that a presence of the 
Qa-1 molecule on self-reactive CD4+ T-cells confers 
protection from lysis mediated by NKG2A+ NK cells. 
In this context, Iwaszko et al. hypothesized that the 
HLA-E polymorphism, resulting in different HLA-E 
surface expression on the potentially pathogenic au-
toreactive T-cells, might determine their susceptibil-
ity to lysis mediated by NKG2A+ NK cells. According 
to this scenario, highly expressed HLA-E*0103 mol-
ecules may be responsible for increased transmission 
of inhibitory signals via CD94/NKG2A receptors, lead-
ing to decreased ability of NK cells to regulate autore-
active T-cells (27).
In our study, we found that the HLA-E*0101/0103X 
heterozygous genotype was significantly more fre-
quent in men with PV, indicating that carrying this 
genotype increased the risk of PV in men. This gen-
otype was also markedly more frequent in the pa-
tient group (65.3% of patients vs. 46.0% of controls; 
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P= 0.084). However the difference was not statistically 
significant, probably due to low sample size. Despite 
the relatively low sample size of our study, it is un-
likely that the nearly twofold increase in HLA-E*0101/
0103X in male patients versus male controls could be 
attributed to a statistical error. Genetic differences 
between men and women have been implicated in 
various sex-specific patterns of susceptibility to au-
toimmune disorders (35). Regarding sex-associated 
risks, while pemphigus is generally a disease which 
is slightly more common in women, our findings may 
be considered as a valid result for men. Nevertheless, 
larger multicenter studies in the Turkish population 
may confirm this sex-specific association.  
To the best of our knowledge, there have been 
no published reports on the association between the 
clinical types of PV and HLA-E polymorphism. Our 
first results investigating this relationship revealed 
that the HLA-E*0101/0103X heterozygous genotype 
was also significantly more frequent in patients with 
mucocutaneous PV, clearly the most frequent type of 
PV in general. This is also consistent with the main re-
sult of our study, indicating this genotype might play 
a role in the susceptibility to PV.
Our study has some limitations: Firstly, the sample 
size of our study was low; however, several published 
studies on PV and HLA associations have similar sam-
ple size. Secondly, this study is only a single-center 
case-control study on a Turkish population, and fur-
ther studies will be required to confirm the implication 
of HLA-E polymorphisms in the pathogenesis of PV.
CONCLUSION
The results of our study indicate possible involve-
ment of HLA-E in the genetic background of PV in the 
Turkish population of Caucasian origin. Carrying the 
HLA-E*0101/0103X genotype may increase the risk of 
PV in male patients. Further studies will be required 
to confirm the role of these HLA-E polymorphisms in 
the pathogenesis of PV. 
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